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ABSTRACT

Insulin Resistance and Hyperinsulinemia Precede Insulin
Deficiency In Hypertransfused Patients with Thalassemia Major

by
Peter Alexander Merkel
1988

Diabetes mellitus

in patients receiving

hypertransfusion therapy

for thalassemia major

attributed to damage to (3 cells.
overload might

lead to

development

impaired

of

thalassemia major
only modestly

(4

is usually

To examine whether

insulin resistance even before the
insulin secretion,

prepubertal,

12

children with

8 pubertal)

with normal

or

impaired glucose tolerance on chelation

therapy were studied.

Each patient received

insulin

to raise plasma

(40 mU/m2-min)

intravenous

insulin to s;80 jzU/ml

for 2

hours while plasma glucose was maintained at

mg/dl

by a variable rate glucose

insulin clamp technique).

infusion

the glucose

reflects total body glucose metabolism
insulin sensitivity.

In prepubertal
l

(M)

90

±

5

(euglycemic

Under these conditions

euglycemia and hyperinsulinemia,

of

iron

of

infusion rate

and

is an

patients with

index

thalassemia major,
similar to those
mg/m2-min,

M values

(319

in prepubertal

P=not significant).

±

23 mg/m2 min)

normal

controls

In contrast,

sensitivity was markedly reduced

in pubertal

(151 ±

in normal

17 vs.

controls,

224

p<0.01).

±

15 mg/m2-min
The reduction

in

were
(315 ±

insulin
thalassemics

pubertal

insulin sensitivity

patients with thalassemia major was correlated with
load

(r= -0.77,

an excessive rise
(p<0.001).

125 mg/dl

but not the prepubertal
in plasma

iron

2-3

thalassemics,

had

insulin levels after oral

Furthermore,

(6.9 mmol/1)

clamp technique),
late

in

p<0.01).

The pubertal,

glucose

41

in response to a

hyperglycemic stimulus
fold greater than normal

standard

(hyperglycemic
early and

insulin and C-peptide responses were demonstrated

in

the pubertal patients.
These data

suggest that

insulin sensitivity

is reduced

in children with thalassemia major when they reach puberty
due,

in part,

increases

in

to chronic

iron overload.

Compensatory

insulin secretion may help maintain normal

glucose tolerance

in the

stage of the disease.

face of

Increased

insulin resistance

insulin secretion due to

insulin resistance may contribute to /3-cell
thalassemia major.

ii
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INTRODUCTION

HISTORY

OF

In

THALASSEMIA

1925,

reported

Drs.

five

cases

splenomegaly,
further

"...

facial

bones,

Cooley

et.

similar
new

to

suggested
anemia,

some

the

early

surprisingly
Cooley's
been

was

first
is

sea"

and

of

developing

has

"peculiar"
by

defect

coined

based

on

"emia"

in

and
This

life

the

or

a

a

form

of

hemolytic
probably

Greek words

term

Bradford

"thalassa"

blood"

use

to

to

be

be

today

"thalassemia"
in

1932.2'4
meaning

reflecting

on

system."2

came

in

this

They

dependent

remains

were

leukemia,

syndrome

and

1

anemia

the

and

cases

new

by

"the

the

proved

eponym

the

discoloration."1
of

and

They

of

cranial

theories

by

meaning

the

some

and

supplanted

the

of

hemolytopoietic

the

Whipple

liver...."

some

"...

first

anemia,

the

of

Lee

classification.2

observations

anemia.

of

while

was

early

"...

skin

Jaksch's

disease

accurate

largely

that

Pearl

appearance

the

separate

in

and

enlargement
with

von

deserved
that

Cooley

enlargement

realized

congenital

term

a

B.

children with

combined

those

These

as

of

caused

al.

entity

some

and

described

children

Thomas

these

known
but
which
The

"the

2
authors'

observations that most cases occurred

Mediterranean descent.
Cooley's

In the more than sixty years

first description of thalassemia,

have been made

in our understanding of

and pathophysiology

in people of

leading to advances

enormous

since
strides

its molecular basis
in the diagnosis and

treatment of this disease.

MOLECULAR BASIS OF THE THALASSEMIAS

The term thalassemia
group of

is used to describe a heterogenous

inherited anemias characterized by decreased

or

absent production of one or more of the polypeptide chains
which make up human hemoglobin.

Most thalassemias

the polypeptide chains of hemoglobin A1
genes
the

are

inherited

in an autosomal

is

When

impaired or

the resulting diseases are referred to as the a-

thalassemias.
molecule

Thalassemia

dominant pattern.

synthesis of the a-globin molecule

absent,

(a2/32).

involve

Similarly,

is reduced,

the /3-thalassemias.

when synthesis of the /3-globin

the resulting syndromes are known as
Other,

rarer,

exist which correspond to defects

forms of thalassemia
in production of various

non-alpha or non-beta hemoglobin chains.5
In /3-thalassemia,

normal

/3-globin genes are present but

are not expressed due to the action of the thalassemia gene
complex that alters /3-globin gene expression.

Although the

3
basic

failure

of

from problems
be

caused

by

/3-globin

in mRNA
any

disturbances

at

more

The

a-thalassemias
of

the

mutations
with
is

30

three

two

Because

are

one

this

a-loci

by

hydrops

have

further

discussion

scope

of

paper.

concerns

of

the

can

causing

gene

expression

been

described.5

problems

H

at

four

syndrome).

hemoglobin

are

results

/3-thalassemia

children with

mutations

only,

have

similar

often

mutations

globin

thalassemia

investigation

this

of

Most

mutations
to

genetic

mutations

(fetal

most

processing,

steps

loci.

similar

synthesis

of

caused

utero

a-loci

or

variety

different

in

clinically

with

a

a-globin

die

template

different

and

both

than

of

chain

one

or

a-loci

Patients

disease

that

intermedia.

Patients

asymptomatic

carriers.

/3-thalassemia

a-thalassemias

is

patients
beyond

the

/3-THALASSEMIAS

Geographic

The
centered

distribution
in

Especially
Greece

Distribution

the
high

(5-15%)

families
country.5

of

of

countries

/3-Thalassemia

the

comprise

children
by

far

Thalassemia

is

for

bordering

frequencies
and

gene

the

occur
from

the

in

found

of
in

is

Mediterranean

Italy

Italian

majority

also

/3-thalassemia

(up

to

5%)

Sea.
and

or Greek

American

patients

in

the

Middle

this

East,

4
Africa and Southern Asia.
Americans

The gene

is approximately 0.8%.6

recent rise

in

decent will

lead to a

frequency
It

in black

is believed that the

immigration of people of Southeast Asian
sharp

cases of thalassemia major

increase

in the number of new

in the United States

in the

coming decade.7'8
The /3-thalassemias are usually classified as
"major"

and

clinical

"intermedia"

"minor,"

forms based on both genotype

and

presentation.

Thalassemia Minor

Individuals with thalassemia minor or thalassemia trait
are heterozygous

for the thalassemia gene and /3-globin

is

synthesized at approximately half the rate of normal,
resulting

in a mild

form of microcytic hypochromic anemia.

Laboratory studies reveal

reduced mean corpuscular volume,

decreased mean corpuscular hemoglobin,
(decreased

decreased hemoglobin

1.0-2.0 g/dl verses age and sex matched controls)

and decreased osmotic

fragility.9

reticulocyte counts are normal

Red blood cell

or somewhat elevated.

Peripheral blood smears show some hypochromia,
poikilocytes,

ovalocytes,

count and

target cells,

and basophilic stippling.

diagnosis can be made by quantitative hemoglobin
electrophoresis showing elevated hemoglobin A2

levels

The

5
(>3.5%).

Although most people with thalassemia minor are

asymptomatic,

some patients complain of easy

fatiguability

and the anemia may be worsened by pregnancy or
deficient

states.5

is useful

in explaining abnormal

findings and
need

Making a diagnosis

in excluding

of thalassemia trait

hematological

laboratory

iron deficiency anemia with

its

for further diagnostic studies and therapy.

Establishment of a diagnosis
ethnic groups and
gene

iron

is the rationale

individuals at high risk

for screening

for carrying the

in order to provide them with genetic counseling.

Thalassemia Major

In contrast to the relatively benign course of
thalassemia minor,

the homozygous state

for /3-thalassemia

leads to a severe chronic hemolytic anemia known as
thalassemia major.

The anemia

is so severe that early death

occurs unless regular blood transfusion
near absence of /3-globin production
to low or absent
an

increase

is

initiated.

in these patients

levels of hemoglobin A^.

for the

leads

Although there

in gamma and delta-chain synthesis,

does not compensate

The

the

is

response

loss of beta-chain production.

Since the rate of a-globin production remains normal,

the

total

number of a-chains greatly outnumber non-a chains.

These

"unbalanced"

a-chains aggregate within red blood cells

6
into unstable

inclusions,

or

"Fessas bodies."5'10'11

inclusion bodies cause death of early red blood cells
bone marrow and markedly shortened survival
reach the circulation.
hemoglobin content,
hypochromic,

Thalassemia

decrease

in production of

Intermedia

10%

of patients with homozygous (3-

thalassemia have clinical

disease with degrees of anemia

symptoms that are

less

severe or delayed than those

described below.

This

syndrome

course.
early

in

microcytic and poikilocytic red blood cells.

Approximately

intermedia.

in the

of those that

Along with the total

this process results

These

is known as thalassemia

These patients vary greatly

They may require only minimal

in the disease,

in their clinical

transfusion support

but splenectomy and

full

transfusion

therapy may eventually be needed.5

CLINICAL FINDINGS

IN UNTREATED THALASSEMIA MAJOR

The clinical manifestations of untreated thalassemia
major are a direct result of hemolytic anemia and become
apparent after the

infant

and

is six months old,

hemoglobin synthesis normally diminishes.

when

fetal

Presenting

7
clinical

features can

irritability,

include pallor,

growth retardation,

to liver and spleen enlargement.5
the severe anemia may be observed.

jaundice,

and abdominal

Cardiac dilation due to
Compensatory marrow

hypertrophy occurs causing the dramatic

skeletal

thalassemia which Cooley first described:

abnormalities,

osteoporosis and early epiphyseal

fusion.2'5

transfusion therapy,
averages

less than

Laboratory

bossing,
severe

The

liver,

suffer enlargement due to

extramedullary hematopoiesis.
from the organ's role

changes of

frontal

maxillary enlargement with dental

kidneys and spleen all

swelling due

Splenomegaly also results

in red blood cell
the

removal.

Without

life expectancy of patients

four years.

findings

in untreated thalassemia major are

those of a severe uncomplicated hemolytic anemia.
about six months of age the hemoglobin
3.0-4.0 g/dl.
hypochromic,
cells as well
above.

Peripheral

level

After

falls as

blood smear reveals the classic

microcytic cells with poikilocytes,

target

as cells with the Fessa bodies described

The reticulocyte count

is between

blood cells are resistant to hemolysis,

a

2-8%.

The red

finding Cooley

first noted and one that helps distinguish the disease
other forms of hereditary hemolytic anemia
congenital

spherocytosis.2

levels of 2.0-4.0 mg/dl.
hemoglobin

low as

fraction

The bilirubin

from

such as
is elevated to

Hemoglobin F is the predominant

(20-60%),

yet the total

hemoglobin

level

8
is still very
increased

low.

The ratio of hemoglobin A2‘^i

from the normal

1:30 to less than

is

1:20.5

THERAPY FOR THALASSEMIA MAJOR

Prevention:

Genetic Counseling

The best treatment
prevention.
births of

is,

of course,

This can only be attained by preventing the

infants homozygous

this goal,
prenatal

for thalassemia major

for thalassemia.

large-scale programs

To achieve

for genetic screening,

diagnosis and genetic counseling have been

established

for populations at high risk

thalassemia gene.

Screening

for carrying the

for thalassemia trait can be

accomplished by measuring mean corpuscular volume and
follow-up quantitative hemoglobin A2

determination

patients with microcytosis.9'12

Prenatal

thalassemia major can be made by

fetal

globin chain
polymorphisms

incorporation studies13'14

not to have children as well
women carrying affected
involved

diagnosis of

blood sampling and
or by DNA

in cells recovered by amniocentesis15

chorionic villus biopsy.16'17

in

Decisions by at-risk

or
families

as therapeutic abortions by

fetuses are options some

families

in the screening programs have taken.

Implementation of comprehensive education and

screening

9
programs
a

for high-risk populations

significant decrease

in the

in

in the number of new cases of

^-thalassemia major through the early
spectacularly successful
the births of affected
Continued effort

1970's resulted

1980's and has been

in Cyprus where more than 90%

of

fetuses have been prevented.8'18

in such preventive measures must be

maintained and modified to account

for any population shifts

of at-risk groups.

Hvootransfusion Therapy

The untreated patient with thalassemia major has a very
short

life expectancy.

It was

recognized early that

transfusions were necessary to sustain the
patients.
overload,
childrens'

life of these

Because of concern over the development of
transfusions were given sparingly.
hemoglobin was sometimes

and they were often symptomatic.
erythroid hyperplasia

minimally transfused patients.
transfusion schedule,

Therefore,

5.0-6.0 g/dl

or lower

deformities that

still present
Furthermore,

a tremendous

in the

even with this

iron burden developed

over the years causing multiple organ disturbances
cardiac

failure,

including

growth and endocrine abnormalities and

liver dysfunction.

The

the

The cardiomegaly,

and severe skeletal

occur in untreated patients were

iron

life expectancy of patients with

10
thalassemia major on this transfusion schedule averaged
15-20 years.5

Hypertransfusion Therapy

The approach to treating patients with thalassemia
major changed dramatically
results of a

in

1964 when Wolman published the

retrospective cross-sectional

survey of

thalassemic patients comparing their average hemoglobin
levels with their clinical
therapy.19

conditions during transfusion

He showed that compared to patients whose

hemoglobin levels were maintained between 4.0-5.9
those patients with hemoglobin
8.0-9.9

g/dl

outcomes.

Patients with higher hemoglobin

facial

fewer skeletal

disfigurement,

hepatosplenomegaly and less
report,

levels maintained between

had significantly better short-term clinical

less growth retardation,
including

g/dl,

levels displayed

abnormalities,

less degrees

of

severe cardiomegaly.

After this

many centers began using transfusion regimens that

kept hemoglobin levels above
to be known as

10.0 g/dl.

"hypertransfusion"

This protocol

therapy.

Numerous

came

studies

have demonstrated the distinct advantages of
hypertransfusion therapy:

normalization of growth,

suppression of erythropoiesis,

decrease

and cardiac enlargement.

importantly,

Most

in liver,

spleen,

by eliminating

11
the anemia and marrow hyperplasia,
patients to lead

full,

active

this

regimen allows

lives without the physical

disfigurement previously seen.5
Hypertransfusion therapy has become the
regimen

standard

for treating patients with thalassemia major

in the

United States and other countries economically capable of
its
a

implementation.

"supertransfusion"

One center's recent
protocol

hemoglobin levels above

hemoglobin

(>14.0 g/dl)

for

is the maintenance of baseline

11.5 g/dl,

compromise between the goal

recommendations

a

level

felt to be a

of maintaining a normal

and the

increased transfusion

requirement that would be required to achieve

such a

level.

Such hemoglobin levels can be achieved by transfusions of
10 ml/kg of

filtered washed packed red blood cells given

every three weeks.20

The Yale-New Haven Hospital

Thalassemia Clinic maintains hemoglobin above
transfusion of

10.0 g/dl

by

15 ml/kg of washed packed red blood cells

every 4-5 weeks.
Although the greater number of transfusions
increase

in the amount of

leads to an

iron received by the patient,

may be offset somewhat by a decrease

in

intestinal

absorption due to correction of anemia.19

this

iron

Nevertheless,

iron overload remains the major cause of morbidity and
mortality in thalassemic patients.
therapy are designed to
increase

iron excretion.

Thus,

adjuvant

increase red blood cell

forms of

survival

and

12
Splenectomy

Before the adoption of transfusion therapy,

patients

with thalassemia major often required early splenectomy due
to massive splenomegaly which caused mechanical
thrombocytopenia and neutropenia.5
hypertransfusion regimens,
occur,

With current

massive splenomegaly does not

although some organ enlargement

However,

splenectomy

symptoms,

is still

is

inevitable.20

indicated when there

is

evidence of a

shortened survival

time of transfused red

blood cells.

After splenectomy,

transfusion requirements

decrease and,

therefore,

is

reduced.

patient

The operation

is at

In

1980

neocytes,

is usually performed when the

immunity to bacteria,

encapsulated organisms,

Experimental

iron burden

least six years old to allow for the

development of humoral

Haemophilus

the patient's acquired

especially

such as Streptococcus pneumoniae and

influenzae.5•20

and

Future Therapies

Propper et.

al.

reported on the use of

red blood cells with a mean age

compared with the mean age of
transfused red blood cells.

60 days

of

20-30 days

for regularly

Such neocytes are harvested

from donors using a continuing

flow cell

separator similar

13
to that used to collect white blood cells.21
that transfused neocytes have prolonged

It was

shown

in vivo survival

compared to traditionally transfused red blood cells.
studies,

however,

have not shown significantly decreased

blood requirements with neocytes
1988,

personal

Other

communication).

(Bove JR and Pearson HA,
Furthermore,

this therapy

involves extreme cost and exposure of patients to an
increased number of blood donors.
rendered neocyte therapy still

These uncertainties have

experimental.20

Bone marrow transplantation

is theoretically a cure

thalassemia major but has carried

significant risks.

for

The

first successful bone marrow transplant of a patient with
thalassemia major was accomplished
followed by a number of trials
children.
patients
a

A recent
10-18

in

in both

series by Lucarelli

years of age reported a

25% mortality rate.23

procedure

in risk-reduction.

The

et.
70%

al.

in 40

success rate but

While a potentially
for

and awaits

further

increased use of the

for genetic and oncologic

continue to help

infants and older

bone marrow transplantation

thalassemia major remains experimental
progress

This was

The therapy currently requires

histocompatible sibling marrow donors.
promising therapy,

1982.22

indications

should

improve the technique's effectiveness and

safety.
The modification of marrow erythroid differentiation
through the use of chemotherapeutic agents

such as

5-

14
azacytidine and hydroxyurea
being considered

is another experimental

approach

for patients with thalassemia major.24-26

IRON OVERLOAD IN HYPERTRANSFUSED PATIENTS WITH THALASSEMIA
MAJOR

Iron

Balance

The normal

homeostasis of

hemoglobin synthesis
mechanisms,

a crucial

as many other

is maintained through complex

plasma proteins,

stores.

intestine.

with apotransferrin to

Dietary

iron

for

Approximately 70%

iron pool

in heme compounds

Another

15-30%

is stored

iron

in the

liver as

iron combines with apoferritin,

iron

is present as hemosiderin,

ferritin.

in the

iron combines

in the plasma.
is normally

(hemoglobin and myoglobin).

when

of

absorbed

a ^-globulin

molecule that acts as a carrier

present

of

system and tissue

In the circulation

of the body's

for

intracellular

is

form transferrin,

element

interactions

the reticulo-endothelial

and red blood cell
upper small

as well

iron,

ferritin,

and a

made up of

formed

smaller amount of
large aggregates

When senescent red blood cells are destroyed

within the reticulo-endothelial
transported by transferrin
synthesis or storage

system,

for use

in tissues.27

the

free

iron

is

in either new hemoglobin

15
The human body has
maintain

flexibility

in

its

iron balance by self-regulating

If tissue

iron accumulates due to

capacity to

iron absorption.

increased oral

intake,

storage capacities of apoferritin and transferrin,
usually only partly utilized,
of gastro-intestinal
Mucosal

causes

On the other hand,

sharply.

interfere with

total

body

iron

iron deficiency

increased binding capacity of transferrin and

decreased
intestinal
excrete

itself can

both

saturated and the rate

iron absorption decreases

iron deposition

absorption.

become

the

iron storage pools
absorption.27

iron

resulting

However,

in

increased gastro¬

the body's

is severely limited.

Transfusions are not the only sources of
thalassemic patients.

body

iron

calculated to have hemosiderosis

iron burdens that exceeded the amount of

known to have been acquired through transfusions.
postulated that
accounted

in

During the hypotransfusion era,

thalassemic patients were
and total

ability to

increased gastro-intestinal

for this difference.28

iron

It was

iron absorption

Early work with

iron

tracer studies demonstrated that patients with
hemoglobinopathies and other
absorb dietary
individuals.29

iron

far

forms of refractory anemias

in excess of normal

Erlandson et.

al.

in

1962

patients with thalassemia major had an
intestinal

non-anemic

demonstrated that

increase

iron absorption compared to normal

the patients'

hemoglobin

levels were

in

children when

6.0-8.5 g/dl

but had

16

normal

intestinal

iron absorption when their hemoglobin

levels were maintained at 9.5-12.6 g/dl.30
this study

found no

absorption

in patients with thalassemia trait.

proposed that the

increased rate of

Furthermore,

increased

iron absorption

related to the

increased

when patients'

hemoglobin levels are

Thus,

the

iron
They

is somehow

ineffective erythropoiesis

decreases markedly when hemoglobin
normal.

intestinal

increased

low.

seen

Iron absorption

levels are restored to

iron administered during

hypertransfusion therapy may be offset somewhat by decreased
gastro-intestinal

iron absorption due to prevention of

severe anemia.
Patients with thalassemia major receive
5-15 mg of transfused
per 250 ml

iron per day

(based on

of packed red blood cells)

with hundreds of units
These patients are

of blood

iron and,

body's normal

if

iron with

iron stores.32

left untreated,
By

1-2

11 years of
received

grams being the

Increasing age and,

increasing number of transfusions results
overload.

be treated

significant

the average hypertransfused patient has

approximately 28 grams of

iron

in their lifetime.31'32

inevitably develop severe hemosiderosis.
age,

200 mg of

and will

incapable of excreting

amounts of this excess

approximately

in a

therefore,

state of

iron

17

Clinical

and Pathological

Complications

The adoption of hypertransfusion therapy has greatly
improved the quality and duration of
thalassemia major.

However,

transfusional hemosiderosis,
morbidity and mortality
Iron overload was
Bradford

in

deposition

1936.3

life

for patients with

a complication of this therapy,
is now the major cause of

in these patients.
first discussed by Whipple

Studies have demonstrated

iron

in multiple organs with pathological

similar to those

seen
also

in

findings

idiopathic hemochromatosis.28'33

Schafer et.

al.

of cardiac,

endocrine and hepatic damage

adult patients given

and

found

similar clinical

intensive

manifestations

in non-thalassemic

short-term transfusion

support.34

The most common pathologic and clinical

of acquired

iron overload are described below.

findings

Cardiac Complications

Cardiac damage and arrhythmias have
recognized as the most
hemochromatosis

long been

severe complications

of

acquired

in thalassemic patients and remain today the

chief cause of death

in most patients.

reported on the cardiac status of a
thalassemia major or thalassemia

In

1964

Engle

series of patients with

intermedia who had been

18

receiving traditional
series,

80%

hypotransfusion therapy.35

of the patients had cardiac

including pericarditis,
and congestive heart

atrial

failure.

life.

23

of 24

clinical

Congestive heart

She noted that the cardiac

failure resulted

in the death of

Engle ascribed these

events to hemochromatosis which was pronounced
Ehlers et.

second group of patients at the

very similar results.36
from congestive heart
mean age at death of

Leon et.

al.

al.

same

The patients

failure were
18.

in

1980

in this

in

reported on

institution

9-33

The patients

studies were not treated with
1979

in the second decade

patients with this diagnosis.

all patients autopsied.
a

involvement

and ventricular arrhythmias

complications generally became evident
of

In that

finding

study who died

years old with a
in both of the

above

iron chelation therapy.

In

studied a group of transfusion dependent

anemia patients with radionuclide cineangiography and
demonstrated a

significant decrease

in ejection

the transfused patients compared to normal
Furthermore,
was

the magnitude of

fraction

in

controls.37

left ventricular dysfunction

inversely correlated with the number of transfusions.

Similar results were

found

in patients with thalassemia

major studied by Freeman et.

al.

in

1983.38

The

results of

chelation therapy on cardiac

function are discussed below.

19
Hepatic Damage

In

1954,

Ellis demonstrated

siderosis at autopsy in
conventionally
pathological

11

of

fibrosis and

13 patients treated

for thalassemia major.28

He described

changes very similar to those seen

idiopathic hemochromatosis.
pathological

liver

findings

transfusion-acquired

in

Other studies reported similar

in thalassemia major33
iron overload.34

Liver

and
function tests

in patients with thalassemia major sometimes reveal
or hypogammaglobulinemia,
factor levels,

moderate decreases

and elevated transaminase

hyper-

in coagulation

levels.5'34

Some

of these changes may be secondary to transfusion-acquired
viral

hepatitis which may

thalassemic patients.39

lead to chronic

liver disease

in

Iron deposition can be carcinogenic

and one case of hepatocellular carcinoma has been reported
in a patient with thalassemia major.40
hepatitis B virus may
malignancy.

Infection with

further predispose patients to liver

As patients with thalassemia

survive

longer,

liver malignancies may become more common and careful
screening may be needed.

20
Endocrinolocric Changes

Multiple endocrinopathies have been associated with
thalassemia major and the role of
findings

is not always clear.

hypertransfusion therapy,
were regularly

in

in these

Before the adoption of

patients with thalassemia major

found to have growth retardation thought

secondary to their anemia.5
resulted

iron overload

Hypertransfusion protocols have

improved growth.

However,

in a

study of

250

patients with thalassemia major begun on chelation therapy,
37%

showed growth that was

and

sex-matched controls.41

the patients
therapy until

in this
later

2

standard deviations below ageIt must be noted that many of

study were not begun on deferoxamine
in life.

Therefore,

growth of early aggressive chelation
delay or absence of sexual maturation
thalassemia major

is very common and

the

results on

is not yet known.

The

in patients with
is

felt to be due to

hemosiderotic damage of the hypothalamus.42-45
Iron deposition has been demonstrated
endocrine glands
adrenal,

including thyroid,

testes and pancreas.22'42'44'45

studies have
adrenal,

studied

in virtually all

found deficiencies

parathyroid,

Furthermore,

in pituitary,

testicular and pancreatic

parathyroid,

function.42'44-49

Problems with sexual maturation are believed to be

secondary

to hypothalamic-pituitary dysfunction and/or possible
gonadal hormonal

insensitivity resulting

in the

21
hypogonadotropic hypogonadism seen
major.44'45'50

in thalassemia

Hypoparathyroidism has been reported

in

patients with thalassemia major and demonstrated by
provocative stimulation tests.44'48'51'52
hypoparathyroidism seen
secondary to acquired

The

in thalassemia major

iron overload.

is

Some authors have

reported elevated thyroid stimulating hormone
patients with thalassemia major.47'48
indicate that despite
and some thyroid

iron deposition

felt

levels

However,

in

most studies

in the thyroid gland

function test abnormalities,

patients with

thalassemia major are generally euthyroid.42'42'47'48'52'54

Iron Chelation Therapy:

Deferoxamine

Without an effective means of removing excess body
stores,

hypertransfused patients with thalassemia major

rapidly develop severe hemosiderosis with

its accompanying

cardiac and endocrinologic complications.
therapy,

iron

while effective

in some

is clearly out of the question
anemic patients.

Therefore,

agent was long sought after.
investigated

Phlebotomy

iron overloaded conditions,

in such transfusion-dependent

an

iron chelating pharmacologic

Various agents were

including penicillamine,

EDTA,

diethylene triamine pentacetate but all were
unsatisfactory.5

and tricalcium
found

22
In I960,

deferoxamine

desferrioxamine),

(also referred to as

a sideraphore obtained

from Streptomyces

pilosus was demonstrated to be a highly specific
chelator.5'55

Oral

deferoxamine

medication was

initially given by

is not well

iron

absorbed.

intramuscular

The

injection,

a

route of administration that proved to be very painful.
Studies

in the

induced

iron excretion could be greatly

continuous

late

1970's demonstrated that deferoxamineincreased by slow,

intravenous administration.5'56

Graziano et.

al.

demonstrated that continuous

administration of deferoxamine was nearly
as the

Subsequently,
subcutaneous

(79%)

intravenous route of administration.57

as effective
Subcutaneous

administration can now be accomplished at home through the
use of portable
choice
combine

infusion pumps and this

for deferoxamine therapy.

is now the method of

Some treatment protocols

intravenous deferoxamine administration during

transfusions with up to 7

days per week subcutaneous

infusion schedules.
In

1968 Wapnick et.

deficiency was
overload.58

al.

reported that ascorbic acid

frequently seen

in people with

iron

Further investigation demonstrated that oral

doses of ascorbic acid repleted body stores and
significantly
excretion

increased deferoxamine-induced urinary

iron

in subjects with transfusion acquired

hemosiderosis.59

Subsequent studies have confirmed these

results and ascorbic acid

replacement therapy

in moderate

23
(100 mg/day),
component of

non-cardiotoxic doses

is now a regular

iron-chelation therapy.5

Hypertransfused patients with thalassemia major treated
with a

regimen of chronic,

slow subcutaneous deferoxamine

and ascorbic acid repletion have been able to excrete up to
100 mg of

iron

in urine per day.5

diminish over time despite the
levels and calculated

This response may

fact that serum ferritin

iron burden remain

increased

in these

patients.20,60,61
Deferoxamine therapy
the potential
patients

seen.5

toxicity of chronic use

suffer

infection,

is generally well

irritation at the

is a

tolerated but
concern.

Some

infusion sites but

tachyphylaxis or hypersensitivity are only rarely

Sensorineural

hearing loss,

impairment and possible cataract

retinal

toxicity,

formation have been

reported with high dose deferoxamine therapy.62-64
impairments were reversible

visual

in only a

with discontinuation of deferoxamine.

These

few of the patients
Regular auditory and

ophthalmologic exams have been suggested

for all patients

receiving deferoxamine.
Compliance with using the subcutaneous
protocol has also proven to be a problem,
adolescent patients.5'20'65'66

infusion

especially among

Despite the

inconvenience,

the great expense and the possible toxicity of therapy,
deferoxamine

is the only known effective

agent available and will

iron chelation

remain the mainstay of therapy

in

hypertransfused patients with thalassemia major until
better agent

is available.

Effectiveness of

Since

its

Deferoxamine

introduction,

investigators have

deferoxamine's ability to affect the clinical
patients with thalassemia major.
reported the results of a

In

1974

studied

course

Barry et.

of
al.

randomized prospective trial

intramuscular deferoxamine chelation therapy

in

liver biopsies.60

chelated control patients had

After

followed

five years,

increased

liver

of

18

hypertransfused patients with thalassemia major
with serial

a

non-

iron

concentrations compared to the chelation-treated patients
who showed minimal

changes

Furthermore,

hepatic

but remained

stable

in

fibrosis

liver

iron stores.

increased

in the chelated patients.

groups showed no significant differences
progression.
of

However,

pubertal

5 untreated patients but

patients.

It

is

in the control

1

likely that clinical

seen because the study only covered
patients were not yet

The two

in clinical

development was delayed

in only

group

of 4

in 4

chelated

differences were not

five years and the

in their twenties,

when the more

severe complications of the hemosiderosis become apparent.
In a small uncontrolled trial,

Cohen et.

al.

demonstrated

25
that liver iron stores could be depleted and the progression
of

liver fibrosis stopped through even more

intensive

deferoxamine therapy.67
Because chronic subcutaneous deferoxamine therapy
relatively new,
followed

from

no large

is

series of patients have been

infancy to their twenties to examine the

clinical benefits of maximum chelation therapy.
Nevertheless,

some

studies have

shown

improved

cardiac

function or at least delayed onset of ventricular failure
with chelation therapy.38'66'68-72

Kaye

and Owen

in

reported on 28 patients with thalassemia major ages
years.68

They found that of

inadequately chelated,

7

that early subclinical
correlated with

1985 Wolfe et.

al.

10.69

They

cardiac

al.

in

1983

In

in patients with

iron-chelation therapy after

found that while

12

of

19

"non-compliant"

Giardina et.

al.

only
in

on patients with thalassemia major begun on
followed

reversed

intensive chelation therapy.38

patients were affected by cardiac disease,

therapy and

demonstrated

iron burden and could be

examined cardiac status

compliant patients was.

patients

left ventricular dysfunction

thalassemia major started on
age

"major"

"well-chelated"

Freeman et.

increased

in some patients after

17

7-23

patients considered

developed

arrhythmias while none of the
developed arrhythmias.

11

1978

for five years.70

only short term and preliminary,

1

1985

of

17

reported

iron-chelation

Their results,

indicated that

while

improved

26
cardiac

health

dysfunction
results

in

1986

of

greatest

cardiac

function

also

damage

in

left

in

15

patients

therapy.
who

had

risk.

therapy

the

to

reach

function
and

their

et.
in

al.

20

deterioration

patients.71

A

current

preliminary
compliant

best

Grisaru

non-compliant
in

myocardial

The

yet

ventricular

involved

revealed

progressive

cardiac

chelation

population

investigation

patients

improved
with

and

chelation

age

the

the

with
the

compliant

of

attained

in

ventricular

study

be

seen

reported

patients
of

delayed

were

twenties,

could

findings

with

of

reduced

chelation

therapy.66
If

cardiac

thalassemia
therapy,
in

1982

disease,

major,

then

deferoxamine
compared

to

could

life

reported

the
be

the

first

therapy

were

patients

years

of

age

trials

of

treated

be

unethical,

infancy
is

reason

started
of

will
to

at

patients

be

an

on

continued
allow

with

data
or

for more

age,

that

Modell

life

from

While

verses

untreated

that

will

group

of

future
patients
treated

conclusions.

deferoxamine

major.

al.

expectancy

a

patients

markedly

et.

their

younger.

of

in

aggressive

However,

collected

death

chelation

rise.

definitive

thalassemia

of

with

increased

follow-up

optimistic

early

in

patients.73

conclusions

randomized

should

evidence

results

based

cause

prevented

expectancy

untreated

20

leading

the

since
There

therapy,

improve

would

if

outcome
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CARBOHYDRATE TOLERANCE IN THALASSEMIA MAJOR

Pancreatic

Iron Deposition

Most autopsy studies of patients with thalassemia major
reveal

severe hemosiderotic pancreatic

pancreatic

fibrosis and

iron deposition

islet cells have been described.28'33
compare the pancreatic

involvement.

findings

Diffuse

in both acinar and
Both of these

studies

in thalassemia major to

idiopathic hemochromatosis.

Previous Studies of Diabetes Mellitus

Diabetes mellitus

is

a well

in Thalassemia Major

known complication of

thalassemia major that generally affects patients beyond
their teenage years.
patients'

carbohydrate

Diabetes mellitus
to

the pathophysiology of these

intolerance

is not totally clear.

in thalassemia has usually been attributed

insulin deficiency

deposited

from the toxic effects of

in pancreatic

experimental model
in

However,

1979 by Awai et.

islets.28'33'46'47'74-79

iron,

An

of acquired hemochromatosis was developed
al..77

These

investigators reported

that rats treated with a regimen of
injection of

iron

as

intraperitoneal

ferric nitrilotriacetic acid,

28
developed diabetic symptoms of hyperglycemia,
ketonuria.
oral

These rats showed decreased

glucose

deposits
of

in the

controls.

iron-treated rats showed marked

liver and pancreas though only small

iron were detected

in the /? cells.

rats were phlebotomized,

When the

their diabetic

granules was present.

felt that their results

indicated the cause

While

disturbance

in pancreatic

in 1964,

Lassman et.

al.

in

iron-treated

in

and a

These authors

of diabetes

in

iron metabolism

islet cells.

isolated cases of diabetes mellitus

thalassemia were known,28'80'81

amounts

iron damage

normal number of /5-cell

or iron deposition

iron

symptoms disappeared

and their pancreases showed no evidence of

hemochromatosis was either a

and

insulin responses to

loading compared to normal

Histopathology of the

glycosuria

and Engle25

1974

were the

systematically study and describe a

in

reported

3

cases

first to

group of patients with

thalassemia major with documented diabetes mellitus.46'47
They reported that of
conventional

8

patients treated with

transfusion therapy,

carbohydrate tolerance and 2
mellitus.

had

They also measured

glucose tolerance tests and

3

had

lifelong

impaired

insulin dependent diabetes

insulin levels during the oral

found

30-minute

insulin

levels

in the thalassemics to be significantly below their
controls.

The authors concluded that these results were

consistent with the theory that diabetes mellitus

in

thalassemia major was a

in the

pancreas.

result on

iron deposition
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Subsequent series of patients with thalassemia major
reported similar findings of hyperglycemic,

hypoinsulinemic

responses to oral

In

glucose tolerance tests.

1976,

McIntosh studied 9 patients with thalassemia major finding 7
patients with chemical diabetes mellitus,
high glucose and
He,

too,

of which had

low insulin responses to glucose

felt the carbohydrate

deficient

4

intolerance was

insulin secretion due to pancreatic

deposition.

Saudek et.

al.

in

1977

secondary to
iron

studied 26 thalassemic

patients with oral glucose tolerance tests with
displaying abnormal
considered
of 22

loading.75

13

patients

glucose tolerance of which 4 were

"diabetic."76

Zuppinger et.

al.

in

1979

found

19

patients with thalassemia major exhibiting abnormal

glucose tolerance with affected patients being hyperglycemic
and hypoinsulinemic during the test.78
studied thalassemics younger than
glucose tolerance tests
abnormal

finding

13

Kattamis et.

years with

al.

intravenous

6 of 27 patients with

results and the thalassemics as a group having

increased glucose and decreased

insulin responses to the

intravenous glucose.82
In contrast to the above
have reported

studies,

some

increased rather than reduced

responses to oral

glucose

with thalassemia major.

investigators
insulin

in some hypertransfused patients
Flynn et.

al.

in

1976 reported the

results of 40 oral glucose tolerance tests performed on

19

patients with thalassemia major over a number of years.48

30
They

found 5 of

19 patients to have

mellitus and low insulin levels.

symptomatic diabetes

However,

3

of the

5

patients with diabetes mellitus had earlier glucose
tolerance studies which had showed
in the

increased

insulin levels

face of only modestly impaired carbohydrate

tolerance.

Finally,

some of the

glucose tolerance had
glucose load.
resistance

These authors

patients with normal

insulin responses to the

suggested that

followed by eventual

possible explanation
observed

increased

13

islet-cell

for the carbohydrate

insulin
failure was a

intolerance

in some of the patients.

Other studies

support these

findings of

hyperinsulinemia and proposed an etiology
resistance.

In

1977

Costin et.

al.

for the

reported on

insulin

10

conventionally transfused patients with thalassemia major
studied before,

and

for 5 years

of hypertransfusion therapy.49
only 1 of the
tolerance
4

10 patients displayed abnormal

normal
control
levels.

The mean peak

insulin

glucose tolerance were
subjects'

oral

study,

However,

half of the

after

8

glucose tolerance

levels of the

4

patients with

significantly higher than the

as wells as the patients'

The authors concluded that

important

institution

glucose

on oral glucose tolerance testing.

years of hypertransfusion treatment,

tests.

the

At the onset of the

surviving patients had abnormal

an

following,

own pretreatment

insulin resistance was

factor explaining the progressive development

31
of carbohydrate

intolerance and that

increased

insulin

levels were required to maintain normoglycemia.
proposed that the etiology of this

insulin resistance was

liver cirrhosis secondary to hemosiderosis.
however,

studied

They also,

acknowledged that progressive /3-cell

additional

factor.

Similarly,

Dandona et.

15 transfusion-treated patients

major and

1 with red blood cell

They

al.

in

an

1983

(14 with thalassemia

aplasia)

proven hemosiderotic hepatic damage.83

damage was

who had biopsyFourteen of the

15

patients had normal glucose tolerance tests but had
significantly

increased

compared to controls.
mellitus.

These

insulin responses during the test
One patient had overt diabetes

investigators thought that the

hyperinsulinemia might represent a compensatory response
induced by

insulin resistance secondary to transfusion-

acquired hemosiderotic hepatic damage.
these

findings

is

limited,

however,

are very variable during oral
Furthermore,
early

augmented

insulin release,

late
as

because plasma glucose

glucose tolerance testing.

insulin secretion due to

seen

in type

could explain the elevated glucose and
observed

in these patients.

Interpretation of

II

loss

diabetics84-86

insulin

levels

of
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THE CURRENT INVESTIGATION

In the present study,
hyperglycemic clamp,

the euglycemic

and oral

insulin clamp,

glucose tolerance test were

employed to determine whether thalassemia major or
treatment with
sensitivity,

frequent transfusions alters

insulin secretion,

The

study

indicate that

impaired
that

in this

normal

field.

The

increasing

insulin sensitivity

increasing

study was designed to

in regard to age and disease

state of subjects that were present
investigations

insulin

or both before the

development of diabetes mellitus.
avoid the problems of bias

its

in previous
findings of the present

iron burden

is accompanied by

in thalassemic patients and

insulin secretion appears to preserve near

glucose tolerance at this

stage of the disease.
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METHODS

SUBJECTS

Patients with thalassemia were drawn

from the

Thalassemia Clinic of the Yale-New Haven Hospital
Center.

The clinic serves patients with thalassemia major

and thalassemia

intermedia.

Greek or Italian ancestry.
age >

8 years;

Almost all

the patients are of

Eligibility criteria

treatment with

maintain a hemoglobin level
deferoxamine

(1.5-2.0 g per kg per day,

absence of diabetes87;

informed consent.
were

invited and
Clinical

prepubertal
±

16.0 ±

12

(numbers 7,

(Tanner I)

intermedia.

9

years.

and

up to 6 days per
infusion over 8-10

ability to give
criteria

agreed to participate.

data are summarized

2.8

and

Fourteen patients who met these

standard deviation)

aged

and the

(15 ml

4-6 weeks to

above 9.0-10.0 g/dl)

given by continuous subcutaneous

hours;

included:

frequent transfusions

packed erythrocytes per kg body weight every

week)

Medical

11)

However,

in Table

subjects aged
and 8 pubertal

10.2

1.

There were

±0.5 years

(Tanner II-V)

4

(mean

subjects

Three of the pubertal patients
carry the diagnoses of thalassemia
they all were requiring similar
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transfusion and chelation treatments as the
major patients and

9

thalassemia

for purposes of this study were

considered as patients with thalassemia major.
were

in good general health,

All

were normally active,

subjects
were

taking no medications other than deferoxamine and ascorbic
acid,

and were

mild elevation

free of overt cardiac disease.

Several

in serum aspartate aminotransferase
1)

but

serum direct bilirubin

had

(SGOT)

concentration

(Table

were normal.

No patient had detectable antibodies to human

immunodeficiency virus or hepatitis B virus,
hepatitis B vaccine had been given.

levels

unless

Subjects

less than

18

years of age showed no evidence of growth retardation
(attained heights between the

5-75 percentiles

for age)

the weight of each patient was within the mean ±
deviation of the expected weight
in one modestly overweight

1

(Table

therapy was assessed to be good

10 patients and

by

1).

or 4,

or poor <3

received between

infusions per week:

infusions per week.

Anti-islet cell

in the thalassemic patients

prepubertal
Eisenbarth

Chelation
fair

in 2

good

>5,

They had

155-585 units of packed red blood cells

during their lifetime.
assayed

1).

All

Compliance with chelation therapy was estimated

frequency of deferoxamine

fair 3

in

except

(patient number 6).

had elevated serum ferritin levels

(Table

standard

for their height,88

subject

and

patients)

in the

antibodies were

(except

for 2

laboratory of Dr.

(Joslin Research Laboratory,

of the patients had a positive titer.

Boston,

George
MA).

None
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Forty-four healthy children
pubertal)
normal

(11 prepubertal

served as age-matched controls

fasting glucose and

illnesses,

(Table

insulin levels,

and were taking no medications.

and adolescent control

subjects were of

and
1).

33
All

had

had no recent
Preadolescent

similar age,

height,

weight and body surface area as corresponding preadolescent
and adolescent thalassemic subjects

(Table

their parents gave written

consent before taking

part

informed

1).

Subjects and

in the study and the protocol was approved by the Human

Investigation Committee of the Yale University School

of

Medicine.

PROCEDURES

All

subjects were admitted to the Children's Clinical

Research Center for 3-4

days

for performance of euglycemic

or hyperglycemic clamp studies and glucose tolerance testing
as well

as annual

status.
patients'

evaluations of cardiac and hematologic

Admissions were timed to coincide with the
next scheduled blood transfusion which was

generally given after completion of the
Developmental

studies.

staging89 was assessed by a physical

examination on the day of admission.

The subjects remained

relaxed and were entertained throughout the studies by
movies.
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All

studies were performed

10-12 hour overnight

fast.

in the morning

following a

Two intravenous catheters were

inserted prior to the clamp studies:

one

in an antecubital

vein for administration of test substances and the other
a hand or distal

forearm vein of the contralateral

blood sampling.

The blood sampling hand was placed

heated box

(60-65

°C)

to

"arterialize"

After a rest period of at

least

blood samples were obtained
glucose and

insulin.

for

in a

blood samples.90

30 minutes,

baseline

fasting

for measurement of plasma

The euglycemic and hyperglycemic clamp

techniques have been described
will

arm

in

in detail

elsewhere91

and

only be briefly outlined below.

Euglycemic Insulin Clamp

The euglycemic

insulin clamp procedure was developed

order to estimate tissue sensitivity to
With this technique,
continuous

infusion

height and weight)

insulin

for 2 hours,

in a dose

designed to raise plasma
same

the plasma glucose

"clamped"

is

in vivo.

is administered as a primed

concentrations to the

increment

insulin

level

in all

for

insulin

subjects.

at the same

in insulin is similar in all

(adjusted

level

subjects,

Because
and the
the amount

of glucose required to maintain euglycemia provides an
of

insulin sensitivity.

When

in

insulin

is

infused

index

in the dose
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used

in the present study

(40 milliunits per square meter of

body surface area per minute),

endogenous glucose production

is usually totally suppressed.92'93
of

Therefore,

the amount

infused glucose reflects the amount of glucose being

metabolized by the tissues of the body.
For the euglycemic clamp protocol,
infusion
Novo,

(40 mU/m2-min)

Princeton,

each subject,

NJ)

of regular human

was administered

insulin

for

(Squibb-

120 minutes.

the plasma glucose concentration was

at approximately 90 mg/dl
infusion of a

a prime-continuous

(5 mmol-1)

In

"clamped"

by simultaneous

20 percent glucose solution.

The glucose

infusion rate was adjusted to maintain euglycemia on the
basis of plasma glucose determinations made at the bedside
every 5 minutes.
intervals

for

Results

Blood was

in thalassemic patients were compared with data

19 healthy controls:

(age

10.1 ±1.0 year,
pubertal

6 Tanner I,

mean ±

prepubertal

standard deviation)

subjects

(age

15.3

were studied under the same conditions.
these normal

20 minute

insulin measurements.

from

Tanner II-V,

also obtained at

±

3.7

subjects
and

years)

Results

13
who

in some of

controls have been reported elsewhere.94
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Hyperglycemic Clamp

The hyperglycemic clamp procedure provides a means to
more precisely quantitate
subjects.

insulin secretion

With this procedure,

in human

exogenous glucose

is given

intravenously to raise plasma glucose levels by the
amount

in each subject and plasma

insulin responses to this

standardized stimulus are determined.
plasma glucose
20 minutes,

By rapidly raising

levels toward the hyperglycemic goal within

the early

(first phase)

quantified accurately and

insulin response can be

independently.91

Hyperglycemic clamp studies were performed
Tanner II-V thalassemic subjects during a
at

least

1 month after the euglycemic

With this procedure,
raised by

same

125 mg/dl

above

5-15 minute period according to a

subsequent visit

insulin clamp study.

the plasma glucose
(6.9 mmol/1)

in the

level was acutely
fasting values

over a

standardized algorithm.91

Plasma glucose was maintained at this hyperglycemic plateau
for the remainder of the study

(120 minutes)

by

determination of the glucose concentration at

5 minute

intervals and appropriate adjustment of a variable rate 20%
glucose

infusion.

Blood

measurement of plasma
8,

10,

20,

40,

Results

60,

80,

samples were also obtained

insulin and C-peptide at
100,

and

0,

for

2,

4,

120 minutes.

in these patients were compared with those

9 healthy Tanner II-V controls

6,

(age

15.7

were studied under the same conditions.

±

3.0 years)

from

who

39
Oral

Glucose Tolerance Test

Oral
morning

glucose tolerance tests were also performed

following an overnight

fast,

two days before or

after the euglycemic clamp procedure.
at a dose of

Glucose was

Results
those

ingested

1.75 g per kg body weight to a maximum of

and blood samples were obtained at -15,
120 minutes

in the

0,

30,

60,

for measurement of plasma glucose and

90

100 g
and

insulin.

in the thalassemic subjects were compared to

in 5 Tanner I,

11 Tanner II-V,

prepubertal

pubertal

(age

(age 9.7

14.8

±

±

2.2

years)

2.0 years),

and

normal

subj ects.

BIOCHEMICAL MEASUREMENTS

Plasma glucose was measured by the glucose oxidase
method using a
Instruments,

Beckman glucose analyzer

Fullerton,

CA).

Plasma

(Diagnostic Products Corporation,

(Beckman

insulin95

Los Angeles,

measured by double antibody radioimmunoassay.
ferritin was measured by a
assay procedure

(Ramco,

and C-peptide
CA)

were

Plasma

solid support radioimmunometric

Inc.,

Houston,

Texas).
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CALCULATIONS AND ANALYSIS

Under steady-state conditions of euglycemia during the
insulin clamp study,
and index of
rate

the rate of glucose

infusion provides

insulin-stimulated glucose metabolism.

This

(expressed as milligrams per square meter of body

surface area per minute)
intervals and adjusted
glucose

level

correction"

was calculated during 20-minute

for deviations

of 90 mg/dl

corrects

(5 mmol/1).

space.91

last

intervals and adjusted
level
same

60 minutes of each

the rate of glucose

(expressed as milligrams per square meter of body

surface area per minute)

is the

of glucose

for comparison.

During the hyperglycemic clamp,

glucose

"space

The average glucose

infusion rate required during the

metabolism

This

for the addition or removal

from the body's glucose

clamp study was used

from the target plasma

of

was calculated during

for deviations

125 mg/dl

above

"space correction"

euglycemic clamp.

In addition,

20-minute

from the target plasma

fasting.

This adjustment

as calculated

for the

the hyperglycemic clamp

results require a correction

for urinary glucose

plasma

responses during the

insulin and C-peptide

hyperglycemic clamp study are biphasic;
and second phase

(10-120 minutes)

first

loss.

The

(0-10 minutes)

responses were calculated

as the mean hormone concentration during the respective time
periods.91
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The General Clinical Research Center CLINFO system was
used for data collection,

collation and analysis.

Demographic data are presented as means ± standard deviation
and all other data are expressed as means ± standard error.
Two group comparisons were made by two-tailed Student's
unpaired t-tests and comparisons between 3 or more groups by
analysis of variance.

Correlations between variables were

examined by least squares linear regression analysis.
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RESULTS

EUGLYCEMIC CLAMP

In prepubertal
glucose

thalassemic children,

infusion required to maintain plasma glucose at

approximately 90 mg/dl
values

the rate of

(319

±

in normal prepubertal

mg/m2 min,

was

children

Figure

1.

similar to

(314

±

41

As previously

insulin-stimulated glucose metabolism was

in normal pubertal

mg/m2-min,

control

p=not significant),

reported,94
reduced

23 mg/m2-min)

p<0.01 vs.

control

prepubertal

subjects

(to 224

controls).

±

However,

15
this

puberty-associated decline was significantly more pronounced
in thalassemic subjects to
pubertal

thalassemics

subjects,

155 ±

(Figure

18 mg/m2-min,

1).

responses to insulin were

Among thalassemic
inversely correlated

with the number of transfusions received
Figure 2),

but not with serum

not significant;

Figure

3).

p<0.01 vs.

(r= -0.77,

ferritin levels

p<0.01;

(r= -0.26,

p=
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ORAL GLUCOSE

Plasma
are

shown

glucose

in

responses

area
in

of

subjects.

In

vs.

6.3

±

In

impaired

the

pubertal

insulin

was

clamp

First
responses
plasma
are

insulin

79

±

14

subjects,

glucose

in

and

prepubertal

thalassemic
As

shown
was

pubertal
vs.

the

area

correlated

metabolism
(r=-0.85,

tolerance

patients,

in

Figure

markedly

controls

other

glucose

insulin

carbohydrate

curve

p<0.001

procedure

in

second

phase

standard
in

were

subjects
/xU/ml

125

pubertal

Figure

responses

thalassemic
one:

a

glucose

compared

range

oral

5,

±

1.7

groups).

under

the

insulin

with

the

rates

determined
p=0.002;

the

greater

(15.3

three

in

with

Figure

of
the

6).

CLAMP

and
to

than

to

glucose

contrast,

inversely

insulin-stimulated

HYPERGLYCEMIC

normal

response

mU-min/ml,

curve

The

pubertal

thalassemics

0.6

euglycemic

in

5.

responses

hyperinsulinemia.

thalassemic

response

and
the

marked

under

4

insulin

within

modestly

spite

TEST

and

Figures

were

thalassemic
was

TOLERANCE

or

plasma
mg/dl

(6.9

thalassemic

7.

Both

markedly

compared
569

insulin

±

to

101

first
higher

and

C-peptide

mmol/1)
and
and

increment

pubertal
second

pubertal

pubertal

controls

vs.

26

±

controls

phase

in

pmol/1

in

2

(phase
/zU/ml

or

44
187

±

14

pmol/1,

828

±

187

pmol.l

Similarly,
C-peptide
pubertal
Despite
the

not

the

vs.

first

higher
of

±

at

57

Also

dietary

or

years

p=not

are

association

±

338

±

22

pmol/1

phase

rise

controls

in

in

)

and

the

or

p<0.01).

circulating
in

Figure

7).

thalassemics,

required

the

/iU/ml

greater

the

mmol/1)

between

2

(p<0.01,

infusion

(6.9

above

to maintain
fasting

pubertal
pubertal

was

thalassemic
controls

significant).

two

the

shown

with

was

Neither

in

of

tolerance

8,

at

oral

yet

the

time

begun

were

responses.

in

of

who

of

oral

patients

glucose

profiles

insulin

from

had

both

glucose

patients

presence

diagnosed

therapy

to

sequential

the

patient

Figure

reduced

of

thalassemic

because

responses

glucose

results

female

intolerance

insulin

when

26

significantly

in

mg/dl

pharmacologic
As

±

concentrations

study

testing.

studies.
enhanced

in

from the

tolerance

or

115

DIABETES

tests

glucose

were

mg/m2-min

presented

tolerance

Their

second

different

46

two:

U/ml

glucose

125

mg/m2min,

WITH

excluded

±

3

than

exogenous

(372

PATIENTS

±

and

insulin

glucose

subjects

phase

concentrations

significantly

(398

47

thalassemics

rate

Pi asma

p<0.01;

were

diabetes.
glucose
any

these

showed
their

observed

teenaged
in
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DISCUSSION

Diabetes mellitus

is a

common,

thalassemic patients requiring

late complication

in (3-

frequent transfusions;

a

problem that has not been totally prevented by use of the
iron chelating agent deferoxamine.96
diabetes

Development of

in this setting has generally been thought to be

due to a direct,

toxic effect of

iron on the pancreatic

islets leading to insulin deficiency.28•33• 46•47•75• 77”79
However,

a

surprising degree of variability

in

responses to oral glucose has been observed

in

hypertransfused thalassemic patients;
high

low,

insulin

normal

and even

insulin levels have been

reported.34,46'48#49,75,7 6,83,97
Several

factors help explain the widely varying

responses to oral glucose
thalassemic patients.

loading that have been observed

studies

included patients

sexual maturity and durations of

treatment which could

impact on

insulin secretion.

failed to stratify patients with normal

tolerance,

impaired glucose tolerance and

Such differences
differences

in

Most studies were cross-sectional

surveys of entire clinic populations that
of different ages,

insulin

These

glucose

frank diabetes.

in carbohydrate tolerance produce marked

in the glycemic stimulus to the (3 cell.
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Insulin resistance has been suggested as a cause of
carbohydrate

intolerance

However,

issue of

the

in thalassemia major.48'49'83

insulin sensitivity

in thalassemia

major has never been directly studied but only

inferred

from

results of oral glucose tolerance tests that showed
exaggerated
test is
of

insulin responses.

inadequate

itself could

in these patients.91

insulin responses to oral
dependent changes

glucose tolerance

for assessing the potential

insulin resistance which

secretion

The oral

in

contribution

affect

Furthermore,

insulin

differences

in

glucose could be related to time-

insulin secretion that occur during the

course of the disease.

To circumvent these problems,

the

euglycemic and hyperglycemic clamp techniques were used to
quantify

insulin action and

controlled conditions

insulin secretion under

in patients with thalassemia and

healthy age-matched control
changes

subjects.

To

on early

in carbohydrate metabolism in thalassemia,

young subjects without diabetes were
Insulin resistance
biological

included

response to endogenous or exogenous

ineffective hormone-receptor
receptor processing.

in the

study.

insulin.

insufficient or

interactions or defective post¬

Either process would result

in the biological

Thalassemia and

only

is defined as a diminished

Such decreased response may be due to

decrease

focus

in

response to

in a

insulin.98

its treatment with multiple

transfusions could alter carbohydrate metabolism by

47
impairing

insulin's action on target tissues.

resistance has been observed
and disease states.

Such

insulin

in a number of physiological

The most common causes are obesity and

type II diabetes mellitus.

These

insulin resistant states

are often accompanied by hyperinsulinemia with either
normoglycemia or hyperglycemia.
induce

insulin resistance.

develops

in such patients,

Hyperglycemia

If overt diabetes mellitus
very large doses

often required to attain adequate control.
insulin resistance
hormone excess,

itself may

of

insulin are

Other causes of

include acanthosis nigricans,

glucocorticoid excess and

growth

lipotrophic

diabetes.98•99
Use of the euglycemic and hyperglycemic clamp
techniques have enabled

investigators to examine

sensitivity in a variety of clinical
methods,

decreased

in types I

and

II

children.94

diabetes mellitus

in both obese and lean

and colleagues at Yale adapted the

insulin clamp technique
With this procedure,

for studies

in

they demonstrated that

puberty is associated with

insulin resistance

and diabetic adolescents.

Furthermore,

in both normal

the decrease

insulin-stimulated glucose metabolism seen
not seen

With these

insulin sensitivity has been demonstrated

patients.92'93'100 Amiel
euglycemic

settings.

insulin

in puberty was

in adult subjects who demonstrated the same

sensitivity as prepubertal
insulin sensitivity

subjects.

in

This decline

insulin

in

in puberty was also demonstrated by

48
Block et.

al.

in

1987

in a very similar study of healthy

children using the euglycemic insulin clamp technique.101
Normal

control

data generated by the Amiel

study also

provided the opportunity to determine whether
responsiveness might be altered

insulin

in hypertransfused

thalassemia patients.
The data
there

is no

inherent defect

thalassemia,
tolerance,

from the current

since normal

and peripheral

in prepubertal

investigation suggest that

in glucose metabolism

insulin secretion,

glucose

insulin sensitivity were observed

thalassemic children.

consistent with previous

in

These

studies which

findings are

failed to

find a

genetic link between thalassemia major and diabetes
mellitus.46'102>103

Pollack et.

al.

studied

with thalassemia major and thalassemia
B,

C and DR antigens.103

They

85 patients

intermedia

for HLA-A,

found no significant

association between thalassemia and HLA-linked

factors known

to be related to the development of diabetes mellitus.
was true

for both the group as a whole and the

with clinical
antibodies

diabetes.

in any of the thalassemic subjects

cell

is

(even

in the

impaired carbohydrate

in agreement with a previous study of

antibodies

with chemical

8 patients

The absence of anti-islet cell

older patients with modestly
tolerance)

This

in 8 thalassemia major patients aged

or insulin-dependent diabetes104

islet¬
15-22

and along

with the HLA studies suggests that an underlying autoimmune
process

is unlikely.105-107
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Nondiabetic pubertal
hand,

were

thalassemic patients,

found to be markedly

the normal decline
puberty94'101

insulin resistant,

even when

in insulin sensitivity that occurs with

is taken

clamp studies,

on the other

into account.

During the euglycemic

insulin-stimulated glucose metabolism was

reduced by over 30%

in the pubertal

with age-matched controls.

This

patients when compared

impairment

in

insulin-

stimulated glucose metabolism was also evident during the
hyperglycemic clamp procedure.

In those studies,

glucose disposal was similar in pubertal
controls,

despite 2-3

concentrations

correlated with an

thalassemics and

fold higher circulating

in the thalassemics.

total

insulin

Insulin resistance was

increased number of transfusions

suggesting that this acquired defect may have resulted
chronic

iron overload

in muscle and

from

liver tissue.

In view of the age of the subjects,

radioactive tracer

techniques were unavailable

for use to determine whether the

reduction

in the pubertal

in

insulin action

occurring at the level
However,

tracer studies

of the

liver,

in normal

thalassemics was

muscle or both.

and

insulin resistant

adult subjects show virtually complete suppression of
hepatic glucose production during 40 mU/m2min
infusions.92'93
peripheral

Therefore,

tissues,

it

is reasonable to assume that

rather than the

liver,

insulin resistance that was observed.
content

in muscle tissue,

insulin

as reported

account

for the

Increased

iron

in chronic

iron

50
overload108 might be particularly

important,

since muscle

has been shown to be the principle site of glucose
utilization under both euglycemic and hyperglycemic
conditions100'109.
resistance,

The cellular mechanisms

leading to this

receptor versus post-receptor abnormalities,

remain to be established.
Serum ferritin levels did not correlate with the degree
of

insulin resistance

the present study.

in the thalassemia major patients

This

finding

is somewhat

in

surprising

since changes

in serum ferritin levels have been thought to

reflect total

body

patients110-112.
patients,

iron stores

in

In studies of

the number of

iron-overloaded
multiply-transfused

lifetime units of blood transfused

was closely correlated with both serum ferritin and

liver

iron concentration only

in patients who had received

units of blood.112'113

At higher levels of transfusions the

increase

in

Saudek et.

ferritin was much less dramatic.
al.

Moreover,

reported no correlation between serum

ferritin levels and patients'
degree of glucose tolerance.76
current

50-100

investigation,

ages,

transfusion history,

Interestingly,

they noted significantly

age and number of transfusions

as

or

in the

increased

in the patients with abnormal

glucose tolerance compared to those with normal

glucose

tolerance.

in the

This relationship was most striking

subset of patients with definite diabetes mellitus.
Inflammation and

liver disease113'114

both raise a

subject's

51
serum ferritin level.
technique

for total

Differences

in the measurement

ferritin,115'116 also

interfere with

this value's usefulness as a measure of body
Thus,

it

better

iron stores.

is possible that transfusion history may be a

indicator of total

iron burden and degree of

hemosiderotic damage than serum ferritin.
Insulin resistance

in the pubertal

was accompanied by exaggerated

thalassemic patients

increases

in plasma

insulin

concentrations during oral glucose tolerance testing,
particularly early

in study.

represent a compensatory
overcome

Although this

increase

insulin resistance,

in

finding could

insulin secretion to

such a cause and effect

relationship can not be definitely established with such
data

in as much as plasma glucose

thalassemic patients.

levels were higher in the

To evaluate this

issue

hyperglycemic clamp studies were performed.
provides an

This procedure

identical hyperglycemic stimulus to all

and allows estimation of both
responses.91'117

It

subjects

first and second phase

insulin

is particularly noteworthy that both

first and second phase
pubertal

further,

insulin responses were

thalassemic subjects.

contrast to the characteristic

increased the

This observation stands
loss of

first phase

in

insulin

release that occurs early in the course of type II
diabetes84-86
carbohydrate

and suggests that the evolution of
intolerance

not strictly comparable.

in these two disease processes

is
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Hyperinsulinemia
result

from either

in patients with thalassemia might

increased pancreatic

decreased hepatic clearance of
caused by
secreted

iron overload.
in the /3 cell

insulin,

Insulin

as a prohormone consisting of the
fragment.

insulin and C-peptide are released

amounts.

C-peptide

due to liver disease

is synthesized and

insulin molecule and the C-peptide
both

insulin release or

levels were,

When secreted,

in equimolar

therefore,

measured during

the hyperglycemic clamp to provide a more reliable
changes

in insulin secretion because hepatic extraction of

this proinsulin
that both
enhanced

fragment

first and

is negligible.118

thalassemics supports the view that

insulin rather than

degradation was primarily responsible
hyperinsulinemia observed
conclusion

impaired

is

increased

in these patients.

in

insulin

for the

is supported by recent autopsy

/3-cell mass

The observation

second phase C-peptide responses were

in the pubertal

oversecretion of

normal

index of

This

findings that

iron overloaded patients with

glucose tolerance.119

On the basis of the

findings of this

investigation,

a

mechanism may be proposed to explain the changing nature of
carbohydrate metabolism

in thalassemia.

In the early

stages

of the disease thalassemic patients show no carbohydrate
intolerance or altered

insulin sensitivity.

increased

peripheral

iron burden,

decreases even

in the

However,

sensitivity to

face of chelation therapy.

with

insulin
At this
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stage,

compensatory

maintain near normal
impairment of
secretion

increases

in

insulin secretion serve to

carbohydrate homeostasis,

insulin action precedes defects

in thalassemia.

Ultimately,

implying that
in

insulin

insulin secretion

fails to keep pace and overt diabetes develops,

as

illustrated by the glucose tolerance test results
patients with diabetes.

Thus,

in the two

the appearance of diabetes

thalassemic patients may be due to a combination of
resistance and

insulin deficiency;

either exhaustion of /9 cells120 or
cells or a combination of these

in

insulin

the deficiency due to
iron deposition

in

islet

factors.

Current chelation therapy has not prevented the
development of carbohydrate
mellitus
major.

in many hypertransfused patients with thalassemia
Further studies are needed to determine the

biochemical
Such

basis for the

insulin resistance

in thalassemia.

investigation might also provide valuable

the pathophysiology of

insulin resistance

conditions such as type II
be

intolerance and diabetes

diabetes.

seen

insight

into

in other

Additionally,

it will

important to determine whether adjunctive therapy with

sulfonylurea hypoglycemic,

that have been shown to

increase

insulin sensitivity,121'122 might delay or prevent the
development of

insulin-dependent diabetes

thalassemic patients by reversing
insulin oversecretion.

in hypertransfused

insulin resistance and
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TABLE

Patient **

Sex

]
2
3
4
5
6
7
8
9
10
11
12

M
F
M
M
F
M
F
M
F
F
F
F

l:

CLINICAL CHARACTERISTICS OF STUDY SUBJECTS

Tanner
Stage

Age
(years.)

tieiftht

Weight

(£B1)

(k£)

Surface
Area(m^)

1
1
1
1
2

9.7
9 8
10.6
10.7
12.4
13.1
13.5
14 9
17.1
18 6
19.1
19.1

130
125
142
145
145
148
158
160
162
152
150
153

28
28
33
34
38
52
58
64
55
54
47
54

1.0
1.0
1.1
1.2
1.2
1.5
1.6
1.7
1.6
1.5
1.4
1.5

!0.2±0.5
16.0+2 8

136+10
153+6

2
3
3
4
4
3
5

Tanner I (mean + SD)
Tanner Il-V (mean + SD)

Normal Controls
(mean + SD)

N

Sex

Tanner 1
Tanner 11-V

1 1
33

8M/3F
16M/17F

31 + 3
53+8

Ferritin Hemoglobin
(ne. ml)
(&M)
2800
1850
1480
2050
883
4940
3900
3370
3350
1470
2950
2500

10.0
8 9
9.8
9.2
9.8
10.8
8.2
12.1
9.6
8.5
9.3
10.7

1.1+0 1
1.5+0.2

Age
(igari)

Height
(cm)

^'e>Rht
(k£>

Surface
Area(m-

9 9+1.5
15.3+2.9

137 + 8
162+11

30+5
55+11

1 1 ±0 1
1.6+0.2

Transf usions
(total units)

SGOT

182
155
229
198
272
343
263
450
400
585
360
545

37
69
26
38
26
57
122
130
88
74
39
47

(LL_L-
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STEADYSTATE
PLASMA
INSULIN
((iU/ml)

Figure Is

Rates of insulin-stimulated glucose metabolism
(upper panel) and steady-state plasma insulin concentrations
(lower panel) during the euglycemic insulin clamp in
prepubertal (Tanner I) and pubertal (Tanner II-V) subjects.
Values (means ± standard error) in prepubertal thalassemics
(TM) are indicated by the stippled bars, pubertal
thalassemics by the hatched bars and aged-matched normal
controls by the open bars.
P value refers to the
significance of difference between pubertal thalassemics and
pubertal controls.
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Figure 2: Relationship between insulin-stimulated glucose
metabolism, as determined by the euglycemic insulin clamp
procedure, and the number of transfusions received in
patients with thalassemia major.
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Figure 3: Relationship between insulin-stimulated glucose
metabolism, as determined by the euglycemic insulin clamp
procedure, and serum ferritin levels in patients with
thalassemia major.
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PLASMA
GLUCOSE
(mg/dl)

TIME (min)

Figure 4: Plasma glucose levels (means ± standard error)
during oral glucose tolerance testing in pubertal, Tanner
II-V thalassemics (closed circles) and prepubertal, Tanner I
thalassemics (open circles).
Normal control range of values
is indicated by the shaded area.
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160

14 0

12.0

AREA UNDER
OGTT

100

INSULIN CURVE
(mU*min/ml)

80
60

4 0

2.0

0

TANNER I

TANNER ll-V

Figure 5: Area under the insulin response curve during oral
glucose tolerance testing in Tanner I (stippled bars) and
Tanner II-V (hatched bars) thalassemics (TM) and age-matched
normal controls (open bars).
Asterisk indicates significant
difference between pubertal thalassemics and pubertal
controls, p<0.001.

60

25000

20000

AREA UNDER
OGTT
15000
INSULIN CURVE
(mU*min/ml)

10000

5000

0
50

100

150

200

250

300

350

400

INSULIN STIMULATED GLUCOSE METABOLISM
(mg/m* • min)

Figrare 6: Correlation between the area under the insulin
response curve and the rate of insulin-stimulated glucose
metabolism as determined by the euglycemic insulin clamp
procedure for all thalassemic subjects.
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MEAN PLASMA
C-PEPTIDE
(pmol/ml)

PHASE I

PHASE II

Figure 7: First and second phase plasma insulin (upper
panel) and C-peptide (lower panel) responses during the
hyperglycemic clamp study in pubertal thalassemics (TM,
hatched bars) and pubertal control subjects (open bars).
Asterisk indicates significant difference vs. corresponding
value in normal controls, p<0.01.
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PATIENT A

TIME (minutes)

Figure 8:

Plasma glucose (closed circles) and insulin (open
circles) levels during sequential oral glucose tolerance
testing in two female thalassemic patients who have
developed diabetes.
Insulin levels marked with an asterisk
(Patient B) were reported as >150 /LxU/ml (1080 pmol/1) ;
actual values may have been greater.
Shaded areas in middle
panels indicate plasma insulin values (means ± standard
error) in normal pubertal control subjects.
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